Mario Lazzarino

14.5k total citations · 3 hit papers
236 papers, 9.8k citations indexed

About

Mario Lazzarino is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Mario Lazzarino has authored 236 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Hematology, 112 papers in Genetics and 82 papers in Pathology and Forensic Medicine. Recurrent topics in Mario Lazzarino's work include Acute Myeloid Leukemia Research (80 papers), Lymphoma Diagnosis and Treatment (79 papers) and Chronic Lymphocytic Leukemia Research (60 papers). Mario Lazzarino is often cited by papers focused on Acute Myeloid Leukemia Research (80 papers), Lymphoma Diagnosis and Treatment (79 papers) and Chronic Lymphocytic Leukemia Research (60 papers). Mario Lazzarino collaborates with scholars based in Italy, United States and Germany. Mario Lazzarino's co-authors include Cristiana Pascutto, Francesco Passamonti, Mario Cazzola, Luca Arcaini, Paolo Bernasconi, Enrica Morra, Matteo Giovanni Della Porta, Alessandro Corso, Elisa Rumi and Luca Malcovati and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Mario Lazzarino

232 papers receiving 9.5k citations

Hit Papers

Time-Dependent Prognostic... 2005 2026 2012 2019 2007 2009 2005 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes
    2007 695 citations Luca Malcovati, Matteo Giovanni Della Porta et al. Journal of Clinical Oncology profile →
  2. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
    2009 623 citations Francesco Passamonti, Enrica Morra et al. Blood profile →
  3. Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making
    2005 618 citations Luca Malcovati, Matteo Giovanni Della Porta et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mario Lazzarino Italy 48 5.6k 5.0k 2.6k 2.6k 2.4k 236 9.8k
Enrica Morra Italy 46 4.5k 0.8× 5.4k 1.1× 2.4k 0.9× 2.5k 1.0× 1.3k 0.5× 238 8.7k
Luca Arcaini Italy 49 2.4k 0.4× 4.9k 1.0× 1.6k 0.6× 4.2k 1.6× 2.3k 1.0× 223 8.7k
Pierre Morel France 39 5.7k 1.0× 5.8k 1.2× 2.7k 1.0× 6.2k 2.4× 4.1k 1.7× 125 13.3k
Curtis A. Hanson United States 63 8.7k 1.6× 10.9k 2.2× 5.3k 2.0× 3.1k 1.2× 1.4k 0.6× 393 14.7k
Sigurður Y. Kristinsson Sweden 46 3.9k 0.7× 2.6k 0.5× 2.2k 0.9× 834 0.3× 1.6k 0.7× 142 6.0k
Uday Popat United States 43 4.0k 0.7× 1.5k 0.3× 1.3k 0.5× 973 0.4× 1.9k 0.8× 396 6.6k
Morton Coleman United States 47 2.1k 0.4× 3.3k 0.7× 1.6k 0.6× 4.8k 1.9× 3.0k 1.2× 306 8.2k
Constantine S. Tam Australia 49 2.6k 0.5× 6.7k 1.3× 1.3k 0.5× 5.4k 2.1× 1.9k 0.8× 401 8.8k
Angelo Michele Carella Italy 38 3.0k 0.5× 1.6k 0.3× 909 0.3× 2.9k 1.1× 2.8k 1.2× 234 6.3k
David J. Inwards United States 49 1.9k 0.3× 2.1k 0.4× 1.3k 0.5× 4.4k 1.7× 3.8k 1.6× 265 8.0k

Countries citing papers authored by Mario Lazzarino

Since Specialization
Citations

This map shows the geographic impact of Mario Lazzarino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Lazzarino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Lazzarino more than expected).

Fields of papers citing papers by Mario Lazzarino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Lazzarino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Lazzarino. The network helps show where Mario Lazzarino may publish in the future.

Co-authorship network of co-authors of Mario Lazzarino

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Lazzarino. A scholar is included among the top collaborators of Mario Lazzarino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Lazzarino. Mario Lazzarino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tedeschi, Alessandra, Giulia Benevolo, Marzia Varettoni, et al.. (2011). Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia. Cancer. 118(2). 434–443. 69 indexed citations
2.
Bernasconi, Paolo, Catherine Klersy, Marina Boni, et al.. (2010). Does cytogenetic evolution have any prognostic relevance in myelodysplastic syndromes? A study on 153 patients from a single institution. Annals of Hematology. 89(6). 545–551. 16 indexed citations
3.
Varettoni, Marzia, Alessandro Corso, Federica Cocito, et al.. (2010). Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance. Medicine. 89(4). 211–216. 14 indexed citations
4.
Arcaini, Luca, Francesca Montanari, Emilio Paolo Alessandrino, et al.. (2008). Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Annals of Oncology. 19(7). 1331–1335. 25 indexed citations
5.
Corso, Alessandro, Marzia Varettoni, Patrizia Zappasodi, et al.. (2007). A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia. 21(7). 1545–1548. 85 indexed citations
6.
Corso, Alessandro, Luciana Barbarano, Silvia Mangiacavalli, et al.. (2007). Bortezomib with HIG-Dose Dexamethasone as First Line Therapy in Patients with Multiple Myeloma Candidates to High-Dose Therapy.. Blood. 110(11). 3595–3595. 8 indexed citations
7.
Corso, Alessandro, Silvia Mangiacavalli, Luciana Barbarano, et al.. (2007). Limited feasibility of double transplant in multiple myeloma. Cancer. 109(11). 2273–2278. 6 indexed citations
8.
9.
Porta, Matteo Giovanni Della, Luca Malcovati, Rosangela Invernizzi, et al.. (2006). Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia. 20(4). 549–555. 89 indexed citations
10.
Regazzi, Mario, I Iacona, Maria Antonietta Avanzini, et al.. (2005). Pharmacokinetic Behavior of Rituximab. Therapeutic Drug Monitoring. 27(6). 785–792. 74 indexed citations
11.
Cairoli, Roberto, Alessandro Beghini, Gianpaolo Nadali, et al.. (2004). Prognostic Impact of C-Kit Mutations in Core Binding Factor-Leukemia.. Blood. 104(11). 2013–2013. 9 indexed citations
12.
Astori, Cesare, Maurizio Bonfichi, G. Pagnucco, et al.. (1997). Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay. British Journal of Haematology. 97(3). 586–588. 6 indexed citations
13.
Alimena, Giuliana, Mario Lazzarino, Enrica Morra, et al.. (1996). Clinical and cytologic characteristics of blastic phase in Ph-positive chronic myeloid leukemia treated with alpha-interferon.. IRIS Research product catalog (Sapienza University of Rome). 10(4). 615–8. 5 indexed citations
14.
15.
Ferrajoli, Alessandra, A.M. Liberati, Emilio Donti, et al.. (1995). Interferon‐α plus low‐dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. European Journal Of Haematology. 55(3). 184–188. 9 indexed citations
16.
Brusamolino, Ercole, Ester Orlandi, Enrica Morra, et al.. (1994). Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy. Annals of Oncology. 5. S53–S57. 31 indexed citations
17.
Alimena, Giuliana, Enrica Morra, Mario Lazzarino, et al.. (1991). IL TRATTAMENTO DELLA LEUCEMIA MIELOIDE CRONICA (LMC) CON INTERFERONE ∅-2B (IFN ∅2B). Haematologica. 76. 50. 1 indexed citations
18.
Orlandi, Ester, Mario Lazzarino, Enrica Morra, et al.. (1991). RISULTATI TERAPEUTICI NELLA LEUCEMIA MIELOIDE ACUTE DELL'ANZIANO STUDIO SU 103 PAZIENTI. Haematologica. 76. 66–68. 5 indexed citations
19.
Lazzarino, Mario, Enrica Morra, Ercole Brusamolino, et al.. (1991). Treatment of terminal‐phase chronic myelogenous leukemia with intermediate‐dose cytarabine and hydroxyurea. Hematological Oncology. 9(6). 299–305. 7 indexed citations
20.
Morra, Enrica, Mario Lazzarino, A Castello, et al.. (1989). Bone marrow and blood involvement by non‐Hodgkin's lymphoma: A study of clinicopathologic correlations and prognostic significance in relationship to the Working Formulation. European Journal Of Haematology. 42(5). 445–453. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Enrica Morra Breakdown of academic impact, for papers by Luca Arcaini Breakdown of academic impact, for papers by Pierre Morel Breakdown of academic impact, for papers by Curtis A. Hanson Breakdown of academic impact, for papers by Sigurður Y. Kristinsson Breakdown of academic impact, for papers by Uday Popat Breakdown of academic impact, for papers by Morton Coleman Breakdown of academic impact, for papers by Constantine S. Tam Breakdown of academic impact, for papers by Angelo Michele Carella Breakdown of academic impact, for papers by David J. Inwards
Rankless by CCL
2026